The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock

• Status: Unknown status
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The first objective of this study was to characterize the pharmacokinetics and pharmacodynamics of daptomycin with a daily dose of 12mg/kg in septic shock patient; the second objective is to identify the optimal dosing scheme for daptomycin among patients with septic shock and to enhance therapeutic outcomes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongda Hospital
• Treatments: Daptomycin

Criteria

Inclusion Criteria:

• ≥18 years and ≤75 years

• confirmed or suspected bloodstream and soft tissue infections caused by a grampositive organism

Exclusion Criteria:

• known hypersensitivity to daptomycin or product excipients

• documented or suspected pneumonia caused by a grampositive organism

• infection with a daptomycin-resistant organism

• presence or history of rhabdomyolysis

• signs or symptoms of myopathy with an elevation of creatine phosphokinase concentrations 6.pregnancy or breast-feeding